生物制药公司Alterity Therapeutics Ltd近日宣布，其针对ATH434的三期临床试验项目已获得美国食品药品监督管理局（FDA）的积极反馈。此次反馈源于双方成功举行的Type C会议，标志着该疗法在监管审批道路上取得关键进展。
ATH434作为公司核心研发项目，此次FDA的认可为其后续临床开发及潜在上市奠定了坚实基础。公司表示将依据监管意见推进三期试验方案优化，加速神经退行性疾病治疗领域的创新突破。
生物制药公司Alterity Therapeutics Ltd近日宣布，其针对ATH434的三期临床试验项目已获得美国食品药品监督管理局（FDA）的积极反馈。此次反馈源于双方成功举行的Type C会议，标志着该疗法在监管审批道路上取得关键进展。
ATH434作为公司核心研发项目，此次FDA的认可为其后续临床开发及潜在上市奠定了坚实基础。公司表示将依据监管意见推进三期试验方案优化，加速神经退行性疾病治疗领域的创新突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.